Literature DB >> 27291330

Can molecular DNA-based techniques unravel the truth about diabetic foot infections?

M Malone1,2,3, I B Gosbell3,4, H G Dickson2,5, K Vickery6, B A Espedido4,7, S O Jensen3,4.   

Abstract

Diabetes foot infections are a common condition and a major causal pathway to lower extremity amputation. Identification of causative pathogens is vital in directing antimicrobial therapy. Historically, clinicians have relied upon culture-dependent techniques that are now acknowledged as both being selective for microorganisms that thrive under the physiological and nutritional constraints of the microbiology laboratory and that grossly underestimate the microbial diversity of a sample. The amplification and sequence analysis of the 16S rRNA gene has revealed a diversity of microorganisms in diabetes foot infections, extending the view of the diabetic foot microbiome. The interpretation of these findings and their relevance to clinical care remains largely unexplored. The advent of molecular methods that are culture-independent and employ massively parallel DNA sequencing technology represents a potential 'game changer'. Metagenomics and its shotgun approach to surveying all DNA within a sample (whole genome sequencing) affords the possibility to characterize not only the microbial diversity within a diabetes foot infection (i.e. 'which microorganisms are present') but the biological functions of the community such as virulence and pathogenicity (i.e. 'what are the microorganisms capable of doing'), moving the focus from single species as pathogens to groups of species. This review will examine the new molecular techniques for exploration of the microbiome of infected and uninfected diabetic foot ulcers, exploring the potential of these new technologies and postulating how they could translate to improved clinical care.
Copyright © 2016 John Wiley & Sons, Ltd. Copyright © 2016 John Wiley & Sons, Ltd.

Entities:  

Keywords:  DNA sequencing; diabetic foot infection; metagenomics; microbiome

Mesh:

Substances:

Year:  2016        PMID: 27291330     DOI: 10.1002/dmrr.2834

Source DB:  PubMed          Journal:  Diabetes Metab Res Rev        ISSN: 1520-7552            Impact factor:   4.876


  7 in total

Review 1.  Role of anaerobes in polymicrobial communities and biofilms complicating diabetic foot ulcers.

Authors:  Steven L Percival; Matthew Malone; Dieter Mayer; Anne-Marie Salisbury; Gregory Schultz
Journal:  Int Wound J       Date:  2018-06-04       Impact factor: 3.315

2.  Next Generation DNA Sequencing of Tissues from Infected Diabetic Foot Ulcers.

Authors:  M Malone; K Johani; S O Jensen; I B Gosbell; H G Dickson; H Hu; K Vickery
Journal:  EBioMedicine       Date:  2017-06-27       Impact factor: 8.143

3.  Incidence and risk factors for developing infection in patients presenting with uninfected diabetic foot ulcers.

Authors:  Limin Jia; Christina N Parker; Tony J Parker; Ewan M Kinnear; Patrick H Derhy; Ann M Alvarado; Flavia Huygens; Peter A Lazzarini
Journal:  PLoS One       Date:  2017-05-17       Impact factor: 3.240

4.  Prevalence of Extended-Spectrum β-Lactamase and Carbapenemase Producers of Gram-Negative Bacteria, and Methicillin-Resistant Staphylococcus aureus in Isolates from Diabetic Foot Ulcer Patients in Ethiopia.

Authors:  Asegdew Atlaw Woldeteklie; Habtamu Biazin Kebede; Abdurezak Ahmed Abdela; Yimtubezinash Woldeamanuel
Journal:  Infect Drug Resist       Date:  2022-08-11       Impact factor: 4.177

5.  Evaluation of short exposure times of antimicrobial wound solutions against microbial biofilms: from in vitro to in vivo.

Authors:  K Johani; M Malone; S O Jensen; H G Dickson; I B Gosbell; H Hu; Q Yang; G Schultz; K Vickery
Journal:  J Antimicrob Chemother       Date:  2018-02-01       Impact factor: 5.790

Review 6.  Microbiology and Antimicrobial Therapy for Diabetic Foot Infections.

Authors:  Ki Tae Kwon; David G Armstrong
Journal:  Infect Chemother       Date:  2018-03

7.  Microbial Diversity of Chronic Wound and Successful Management of Traditional Chinese Medicine.

Authors:  Minfeng Wu; Yan Li; Dongjie Guo; Gang Kui; Bin Li; Yu Deng; Fulun Li
Journal:  Evid Based Complement Alternat Med       Date:  2018-07-09       Impact factor: 2.629

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.